Where does Stoke Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$50M+13.7%	-$57.93M-51.1%	-$38.35M-63.3%	-$23.48M-121%	$112.88M+1,177%
Depreciation and amortization	$439K+8.4%	$405K-8.4%	$442K-0.9%	$446K-6.5%	$477K-9.3%
Stock-based compensation	$8.75M-11.1%	$9.85M+22.5%	$8.04M+5.8%	$7.6M+12.5%	$6.75M-5.4%
Change in accounts receivable	-$1.49M—	——	——	——	$1.33M+10,500%
Change in other assets	$3.59M—	——	——	$5.18M+321%	$1.23M-29.4%
Change in deferred revenue	-$2.19M—	——	-$4.06M+59.6%	-$10.04M-206%	$9.43M+145%
Net cash from operating activities	-$60.58M—	——	——	——	$131.83M+668%
Capital expenditures	$353K+52.2%	$232K+75.8%	$132K-14.3%	$154K+1.3%	$152K+262%
Net cash from investing activities	$50.69M+183%	-$61.06M—	$0+100%	-$148.48M-1,189%	$13.63M—
Proceeds from issuance of common stock	$3.21M-29.7%	$4.56M+83.2%	$2.49M+349%	$554K-44.8%	$1M+77.1%
Net cash from financing activities	$84.33M-8.7%	$92.34M+2,860%	$3.12M+463%	$554K-59.7%	$1.37M+142%
Net increase (decrease) in cash	$74.44M—	$0+100%	-$18.15M+89.5%	-$173.35M-218%	$146.83M+773%
Depreciation	$439K+8.4%	$405K-8.4%	$442K-0.9%	$446K-6.5%	$477K-9.3%
Increase Decrease In Accounts Payable Accrued Liabilities And Opertaing Leases	-$15.72M-277%	$8.9M+82.4%	$4.88M+76.5%	$2.77M-41.7%	$4.74M+118%
Deferred revenue	-$2.19M—	——	-$4.06M+59.6%	-$10.04M-206%	$9.43M+145%
Increase (Decrease) in Prepaid Expense and Other Assets	$3.59M—	——	——	$5.18M+321%	$1.23M-29.4%
Reduction In Carrying Amount Of Operating Lease Right Of Use Assets	$608K-6.5%	$650K+18.8%	$547K-10.6%	$612K+2.2%	$599K+2.9%
Proceeds From Controlled Equity Offering Sales Agreement Net Of Commissions	——	$21.95M0.0%	$21.95M0.0%	$21.95M0.0%	$21.95M+880%
Proceeds From Issuance Of Common Stock In Controlled Equity Offering Sales Agreement	$80.66M—	——	——	——	$0—
Proceeds from issuance of common stock relating to employee stock plans	$465K—	——	$632K—	——	$370K—
Accrued payables for capital expenditures	$334K-14.4%	$390K+851%	$41K+70.8%	$24K-11.1%	$27K-46.0%
Free cash flow	-$60.94M—	——	——	——	$131.68M+667%
Free cash flow	-$60.94M—	——	——	——	$131.68M+667%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Stoke Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.